The purpose was to compare the incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. This is a single-center, retrospective case–control study. All patients treated with intravitreal injection of ranibizumab, bevacizumab, aflibercept, or corticosteroids for a variety of retinal vascular diseases between 1 October 2014 and 30 November 2018 were included. The total number of patients and injections were determined from a review of billing code and practice management records. Endophthalmitis cases were determined from billing records and then confirmed with chart review. A 24-month period when topical antibiotics were prescribed after intravitreal injection was compared with a 24-month period when topical antibiotics were not prescribed. Between 1 October 2014 and 30 November 2018, a total of 33,515 intravitreal injections were performed and 13 cases of post–intravitreal injection endophthalmitis were identified (incidence rate of 0.0388%; 95% confidence interval, 0.0217%–0.0644%) or approximately 1 case for every 2578 intravitreal injections. Between 1 October 2014 and 31 October 2016, while topical antibiotic prophylaxis was used postoperatively, 14,828 intravitreal injections were performed and 5 cases of endophthalmitis were reported (0.0337%; 95% confidence interval, 0.0129%–0.0739%). Between 1 November 2016 and 30 November 2018, while no prophylaxis was used, 18,687 intravitreal injections were performed and 8 cases of endophthalmitis were identified (0.0428%; 95% confidence interval, 0.0202%–0.0808%). There were no statistical differences in the incidence rates between the two groups (p = 0.675). The incidence rate of endophthalmitis in the group with topical antibiotic prophylaxis after intravitreal injection was similar to the group with no prophylaxis. Changing the current clinical practice to no antibiotic prophylaxis had no effect on the incidence of endophthalmitis.

Diabetic macular edema (DME) is the most common cause of visual loss in diabetic patients. Anti- vascular endothelial growth factors (anti-VEGF) agents are considered first line therapy for DME. Nevertheless, response to anti-VEGF treatment is variable and up to 60% of patients (depending on the anti-VEGF drug used) have an incomplete response to treatment. Several cytokines were demonstrated to be increased in aqueous humour of patients with DME and differences in response to treatment may be related to baseline cytokine levels. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents. Steroids have a different pharmacological profile and act on different pathophysiologic mechanisms. Their effect on aqueous humour cytokines is different from the effect of anti-VEGF therapy. This review highlights the major cytokines involved in DME and evaluates if baseline cytokine levels could be predictors of response to treatment in DME. SIGNIFICANCE STATEMENT Anti-vascular endothelial growth factors (anti-VEGF) agents are effective in the treatment of diabetic macular edema (DME). However, in some cases, DME fails to respond to anti-VEGF intravitreal injections. Changes in cytokine levels after treatment supported the idea that other cytokines than VEGF are implicated in DME pathogenesis and could be predictors of response to anti-VEGF treatment or corticosteroids allowing targeted and individualized therapy guided by cytokine levels.

Background: Retinal diseases are emerging as a significant health concern, making early detection and prompt treatment crucial to prevent visual impairment. Optical coherence tomography (OCT) is the preferred imaging modality for non-invasive diagnosis. Both diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO) present an increase in retinal thickness, posing etiologic diagnostic challenges for non-specialists in retinal diseases. The lack of research on deep learning classification of macular edema secondary to RVO using OCT images motivated us to propose a convolutional neural network model for this task. Methods: The VGG-19 network was fine-tuned with a public dataset to classify OCT images. This network was then used to develop three models: unimodal—the input is only the OCT B-scan; multimodal—the inputs are the OCT B-scan and diabetes information, and multi-image—the inputs are the OCT B-scan, the infrared image, and the diabetes information. Seven hundred sixty-six patients from ULS São João were selected, comprising 208 healthy eyes, 207 with macular edema secondary to RVO, 218 with DME, and 200 with other pathologies. The performance metrics include accuracy, precision, recall, F_0.5 score, and area under the receiver operating characteristic curve (AUROC). Results: The multi-image model achieved better results, with an accuracy of 95.20%, precision of 95.43%, recall of 95.20%, F_0.5-score of 95.32%, F₁-score of 95.21%, and AUROC of 99.59% on the classification task between four classes. Conclusions: This study presents a novel method to distinguish macular edema secondary to RVO and DME using diabetes diagnosis, OCT, and infrared images. This research aims to provide a reliable tool for ophthalmologists, improving the accuracy and speed of diagnoses.

Introduction: COVID-19 is caused by the coronavirus SARS-CoV-2. Ocular manifestations have been reported including conjunctivitis and retinal changes. Therefore, it is of the utmost importance to clarify eye involvement in COVID-19 in order to help with its diagnosis and to further prevent its transmission. The purpose of this review is to describe the structure and transmission of SARS-CoV-2, reported ocular findings and protection strategies for ophthalmologists.Material and Methods: Literature search on PubMed for relevant articles using the keywords ‘COVID-19’, ‘coronavirus’, and ‘SARS-CoV-2’ in conjunction with ‘ophthalmology’ and ‘eye’. Moreover, official recommendations of ophthalmological societies were reviewed.Results: Although the conjunctiva is directly exposed to extraocular pathogens, and the mucosa of the ocular surface and upper respiratory tract are connected by the nasolacrimal duct, the eye is rarely involved in human SARS-CoV-2 infection and the SARS-CoV-2 RNA positive rate by RT-PCR test in tears and conjunctival secretions from patients with COVID-19 is also extremely low.Discussion: The eye can be affected by SARS-CoV-2, which is supported by some reports of conjunctivitis and retinal changes, but its role in the spread of the disease is still unknown.Conclusion: Given the current scarce evidence, more research is needed to clarify the relationship between SARS-CoV-2 and the eye. Introdução: COVID-19 é o nome atribuído à doença causada pelo novo coronavírus - SARS-CoV-2. Esta infeção rapidamente atingiu uma disseminação mundial, face ao aumento da globalização e adaptação do vírus a ambientes distintos. Foram descritas manifestações oftalmológicas em doentes com COVID-19, nomeadamente, conjuntivite e alterações retinianas. Assim, é fundamental esclarecer o envolvimento ocular na COVID-19, contribuindo para o seu diagnóstico precoce e limitando a sua transmissão. O objetivo desta revisão é descrever a estrutura e o modo de transmissão do SARS-CoV-2, assim como manifestações oculares reportadas e estratégias de proteção para oftalmologistas.Material e Métodos: Revisão dos artigos relevantes publicados na PubMed usando as palavras-chave ‘COVID-19’, ‘coronavirus’ e ‘SARS-CoV-2’ em associação com as palavras ‘ophthalmology’ e ‘eye’. Além disso, foi feita uma revisão das recomendações oficiais de várias sociedades oftalmológicas a nível mundial.Resultados: Apesar da conjuntiva estar diretamente exposta a patógenos exógenos, e da mucosa da superfície ocular e do trato respiratório superior estarem conectados pelo canal nasolacrimal, o olho raramente parece ser afetado pelo SARS-CoV-2. A infeção por SARS-CoV-2 e a taxa de positividade para a pesquisa do RNA do SARS-CoV-2 pelo teste de RT-PCR em lágrimas e secreções conjuntivais de pacientes com COVID-19 também são extremamente baixas.Discussão: O olho pode ser afetado pelo SARS-CoV-2, dada a descrição de casos de conjuntivite e alterações retinianas, mas o seu papel na disseminação da doença ainda é desconhecido.Conclusão: Dada a escassa evidência atual, são necessários mais estudos para esclarecer a relação entre o SARS-CoV-2 e o globo ocular.

Purpose. This study aimed to evaluate the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) injections in the treatment of choroidal neovascularization (CNV) associated with angioid streaks. Methods. Multicenter retrospective cohort study, including eyes with CNV secondary to angioid streaks treated with anti-VEGF injections, were performed. Best-corrected visual acuity (BCVA) in ETDRS letters; qualitative and quantitative (foveal thickness) OCT parameters; anti-VEGF type; and number of injections were collected at baseline and at 3, 6, 12, 24, 36, 48, 60, and 72 months. Results. Thirty-nine eyes from 29 patients, 17 (58.6%) females, were included. The mean follow-up time was 69.4 ± 34.5 months. BCVA was 59.3 ± 23.3 letters at baseline and 63.7 ± 21.9 letters at 48 months. At 3 months, BCVA improved 6.9 ± 11.7 letters ( ). Then, BCVA remained stable. The mean foveal thickness decreased from 343.3 ± 120.2 μm at baseline to 268.3 ± 65.4 at 48 months ( ). The mean number of injections was 4.6 ± 2.1 at 12 months, decreasing to 1.7 ± 2.4 injections between 36 and 48 months ( ). Conclusion. This real-world study suggests that the functional and morphologic response to anti-VEGF therapy for CNV related to angioid streaks is generally satisfactory and maintained in the long term.